Cellular immunotherapy for septic shock: A phase I clinical trial

American Journal of Respiratory and Critical Care Medicine

Volumn 197, Issue 3, 2018, Pages 337-347

  McIntyre, Lauralyn A ^a,b,d   Stewart, Duncan J ^c,d   Mei, Shirley H J ^d   Courtman, David ^d   Watpool, Irene ^d   Granton, John ^b   Marshall, John ^e   Dos Santos, Claudia ^e   Walley, Keith R ^f   Winston, Brent W ^g   Schlosser, Kenny ^d   Fergusson, Dean A ^b,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Department of Epidemiology and Community Medicine ^*  (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

Allogeneic; Bone marrow; Mesenchymal stem cells; Phase I clinical trial; Septic shock

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; VASOACTIVE AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BLEEDING; CLINICAL ARTICLE; COHORT ANALYSIS; FALSE ANEURYSM; FEMALE; HEART ARRHYTHMIA; HEART RATE; HOSPITAL INFECTION; HOSPITAL READMISSION; HUMAN; IMMUNOTHERAPY; LENGTH OF STAY; LUNG EMBOLISM; MALE; MEAN ARTERIAL PRESSURE; MESENCHYMAL STEM CELL TRANSPLANTATION; MYCOSIS; OBSERVATIONAL STUDY; OPEN STUDY; PERICARDITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY ANEURYSM; SAFETY; SEPTIC SHOCK; AGE; ALLOGRAFT; CLINICAL TRIAL; CONFIDENCE INTERVAL; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PROCEDURES; RISK ASSESSMENT; SEX FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ALLOGRAFTS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; RISK ASSESSMENT; SEX FACTORS; SHOCK, SEPTIC; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85045273837     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201705-1006OC     Document Type: Article

References (48)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840-851.
2. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012;40:754-761.
3. Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007;20:345-352.
4. Nduka OO, Parrillo JE. The pathophysiology of septic shock. Crit Care Clin 2009;25:677-702.
5. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ 2016;353:i1585.
6. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014;20:195-203.
7. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182:1047-1057.
8. dos Santos CC, Murthy S, Hu P, Shan Y, Haitsma JJ, Mei SH, et al. Network analysis of transcriptional responses induced by mesenchymal stem cell treatment of experimental sepsis. Am J Pathol 2012;181:1681-1692.
9. Gonzalez-Rey E, Anderson P, Gonz lez MA, Rico L, B scher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929-939.
10. N meth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42-49.
11. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010;28:2229-2238.
12. Lalu MM, Sullivan KJ, Mei SH, Moher D, Straus A, Fergusson DA, et al. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial. eLife 2016;5:5.
13. Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med 2017;196:266-273.
14. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al.; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012;7:e47559.
15. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3:24-32.
16. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014;15:39.
17. Galstian GM, Parovichnikova EN, Makarova PM, Kuzmina LA, Troitskaya VV, Gemdzhian E, et al. The results of the Russian clinical trial of mesenchymal stromal cells (MSCs) in severe neutropenic patients (pts) with septic shock (SS) (RUMCESS trial) [abstract]. Blood 2015;126:2220.
18. McIntyre L, Stewart DJ, Mei SH, Courtman D, Watpool I, Granton J, et al. Cellular Immunotherapy for Septic Shock (CISS): a phase 1 trial [abstract]. Cytotherapy 2017;19(Suppl 5):e3-e4.
19. Schlosser K, McIntyre L, Wang J, Watpool I, Winston B, Walley K, et al. Serial assessment of systematic levels of proinflammatory cytokins in septic shock patients treated with allogeneic mesenchymal stem cells [abstract]. Cytotherapy 2017;19(Suppl 5):e5.
20. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-720.
21. Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The International Sepsis Forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005;33:1538-1548.
22. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010;12:576-578.
23. Casiraghi F, Remuzzi G, Abbate M, Perico N. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev 2013;9: 65-79.
24. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.; Surviving Sepsis Campaign Guidelines Committee including the pediatric subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
25. Marshall J. Multiple organ dysfunction syndrome (MODS). In: Sibbald WJ, Vincent JL, editors. Clinical trials for the treatment of sepsis. Berlin: Springer-Verlag; 1995. pp. 122-138.
26. Pandharipande PP, Shintani AK, Hagerman HE, St Jacques PJ, Rice TW, Sanders NW, et al. Derivation and validation of Spo2/Fio2 ratio to impute for Pao2/Fio2 ratio in the respiratory component of the Sequential Organ Failure Assessment score. Crit Care Med 2009;37: 1317-1321.
27. Marshall JC. Measuring organ dysfunction in the intensive care unit: why and how? Can J Anaesth 2005;52:224-230.
28. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014;2:1016-1026.
29. Chien MH, Bien MY, Ku CC, Chang YC, Pao HY, Yang YL, et al. Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation in lipopolysaccharide-induced acute lung injury. Crit Care Med 2012;40:1245-1253.
30. Lalu MM, McIntyre LL, Stewart DJ. Mesenchymal stromal cells: cautious optimism for their potential role in the treatment of acute lung injury. Crit Care Med 2012;40:1373-1375.
31. Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, et al.; Cardiovascular Cell Therapy Research Network. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation 2013;127: 1630-1635.
32. Lombardo E, van der Poll T, DelaRosa O, Dalemans W. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells 2015;7:368-379.
33. Pedrazza L, Lunardelli A, Luft C, Cruz CU, de Mesquita FC, Bitencourt S, et al. Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model. Inflamm Res 2014;63:719-728.
34. Yagi H, Soto-Gutierrez A, Navarro-Alvarez N, Nahmias Y, Goldwasser Y, Kitagawa Y, et al. Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Mol Ther 2010;18:1857-1864.
35. Zhao X, Liu D, Gong W, Zhao G, Liu L, Yang L, et al. The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells 2014;32:521-533.
36. Maron-Gutierrez T, Silva JD, Asensi KD, Bakker-Abreu I, Shan Y, Diaz BL, et al. Effects of mesenchymal stem cell therapy on the time course of pulmonary remodeling depend on the etiology of lung injury in mice. Crit Care Med 2013;41:e319-e333.
37. Li J, Li D, Liu X, Tang S, Wei F. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm (Lond) 2012;9:33.
38. Zhao YF, Xiong W, Wu XL. Mesenchymal stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Mol Med Rep 2014; 9:1583-1589.
39. Yang JX, Zhang N, Wang HW, Gao P, Yang QP, Wen QP. CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats. J Biol Chem 2015;290: 1994-2006.
40. Zhao YF, Luo YM, Xiong W, Ding W, Li YR, Zhao W, et al. Mesenchymal stem cell-based FGF2 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Eur Rev Med Pharmacol Sci 2015;19: 857-865.
41. Luo CJ, Zhang FJ, Zhang L, Geng YQ, Li QG, Hong Q, et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 2014;41:123-129.
42. Fran ois M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-g licensing. Cytotherapy 2012;14:147-152.
43. Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke L, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells 2014;32: 2430-2442.
44. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013;15:2-8.
45. Devaney J, Horie S, Masterson C, Elliman S, Barry F, O'Brien T, et al. Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 2015;70:625-635.
46. Gramlich OW, Burand AJ, Brown AJ, Deutsch RJ, Kuehn MH, Ankrum JA. Cryopreserved mesenchymal stromal cells maintain potency in a retinal ischemia/reperfusion injury model: toward an off-the-shelf therapy. Sci Rep 2016;6:26463.
47. Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner D, McKenna DH, et al. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. Stem Cells Transl Med 2015;4:615-624.
48. Luetzkendorf J, Nerger K, Hering J, Moegel A, Hoffmann K, Hoefers C, et al. Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. Cytotherapy 2015;17:186-198.